Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.
<h4>Objectives</h4>To investigate the cost-effectiveness of abatacept (ABA) as first-line (1L) therapy in Japanese rheumatoid arthritis (RA) patients using data from the Institute of Rheumatology, Rheumatoid Arthritis database.<h4>Methods</h4>A decision-analytic model was use...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0277566 |
| _version_ | 1828069966846361600 |
|---|---|
| author | Eiichi Tanaka Eisuke Inoue Ayako Shoji Jonas Nilsson Christos Papagiannopoulos Devender Dhanda Yuri Yoshizawa Mai Abe Kumiko Saka Eri Sugano Naohiro Sugitani Moeko Ochiai Rei Yamaguchi Katsunori Ikari Hisashi Yamanaka Masayoshi Harigai |
| author_facet | Eiichi Tanaka Eisuke Inoue Ayako Shoji Jonas Nilsson Christos Papagiannopoulos Devender Dhanda Yuri Yoshizawa Mai Abe Kumiko Saka Eri Sugano Naohiro Sugitani Moeko Ochiai Rei Yamaguchi Katsunori Ikari Hisashi Yamanaka Masayoshi Harigai |
| author_sort | Eiichi Tanaka |
| collection | DOAJ |
| description | <h4>Objectives</h4>To investigate the cost-effectiveness of abatacept (ABA) as first-line (1L) therapy in Japanese rheumatoid arthritis (RA) patients using data from the Institute of Rheumatology, Rheumatoid Arthritis database.<h4>Methods</h4>A decision-analytic model was used to estimate the cost per American College of Rheumatology response of at least 50% improvement (ACR50) responder and per patient in Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) remission from a Japanese healthcare payers' perspective over a 2-year time horizon. Clinical characteristics of patients on ABA-1L were matched with those of patients on ABA second or later line (2L+) or tumour necrosis factor inhibitor (TNFi)-1L directly or using propensity scores. Resource utilisation and medical costs were calculated from the Japan Medical Data Center claims database. Parameter uncertainty was addressed by sensitivity and subgroup analyses (age, treatment duration, Japanese version of Health Assessment Questionnaire [J-HAQ] score).<h4>Results</h4>Incremental costs per member per month (ΔPMPM) for ABA-1L versus TNFi-1L and ABA-2L+ were -1,571 Japanese Yen (JPY) and 81 JPY, respectively. For ABA-1L versus TNFi-1L, ΔPMPM by ACR50 response was -11,715 JPY and by CDAI and SDAI remission 11,602 JPY and 47,003 JPY, respectively. Corresponding costs for ABA-1L were lower for all outcome parameters versus those for ABA-2L+. Scenario analyses showed that ABA-1L was cost-effective over TNFi-1L in patients <65 years for any outcome. Furthermore, ABA-1L was cost-effective over ABA-2L+ for all outcomes in patients with age <65 years, disease duration <5 years and J-HAQ ≥1.5.<h4>Conclusions</h4>ABA-1L demonstrated a favourable cost-effectiveness profile in RA patients, accruing savings for the Japanese healthcare payers. |
| first_indexed | 2024-04-11T00:28:45Z |
| format | Article |
| id | doaj.art-b9f67ed2f1674d6f857010e0f0230030 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T00:28:45Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-b9f67ed2f1674d6f857010e0f02300302023-01-08T05:31:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011711e027756610.1371/journal.pone.0277566Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data.Eiichi TanakaEisuke InoueAyako ShojiJonas NilssonChristos PapagiannopoulosDevender DhandaYuri YoshizawaMai AbeKumiko SakaEri SuganoNaohiro SugitaniMoeko OchiaiRei YamaguchiKatsunori IkariHisashi YamanakaMasayoshi Harigai<h4>Objectives</h4>To investigate the cost-effectiveness of abatacept (ABA) as first-line (1L) therapy in Japanese rheumatoid arthritis (RA) patients using data from the Institute of Rheumatology, Rheumatoid Arthritis database.<h4>Methods</h4>A decision-analytic model was used to estimate the cost per American College of Rheumatology response of at least 50% improvement (ACR50) responder and per patient in Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) remission from a Japanese healthcare payers' perspective over a 2-year time horizon. Clinical characteristics of patients on ABA-1L were matched with those of patients on ABA second or later line (2L+) or tumour necrosis factor inhibitor (TNFi)-1L directly or using propensity scores. Resource utilisation and medical costs were calculated from the Japan Medical Data Center claims database. Parameter uncertainty was addressed by sensitivity and subgroup analyses (age, treatment duration, Japanese version of Health Assessment Questionnaire [J-HAQ] score).<h4>Results</h4>Incremental costs per member per month (ΔPMPM) for ABA-1L versus TNFi-1L and ABA-2L+ were -1,571 Japanese Yen (JPY) and 81 JPY, respectively. For ABA-1L versus TNFi-1L, ΔPMPM by ACR50 response was -11,715 JPY and by CDAI and SDAI remission 11,602 JPY and 47,003 JPY, respectively. Corresponding costs for ABA-1L were lower for all outcome parameters versus those for ABA-2L+. Scenario analyses showed that ABA-1L was cost-effective over TNFi-1L in patients <65 years for any outcome. Furthermore, ABA-1L was cost-effective over ABA-2L+ for all outcomes in patients with age <65 years, disease duration <5 years and J-HAQ ≥1.5.<h4>Conclusions</h4>ABA-1L demonstrated a favourable cost-effectiveness profile in RA patients, accruing savings for the Japanese healthcare payers.https://doi.org/10.1371/journal.pone.0277566 |
| spellingShingle | Eiichi Tanaka Eisuke Inoue Ayako Shoji Jonas Nilsson Christos Papagiannopoulos Devender Dhanda Yuri Yoshizawa Mai Abe Kumiko Saka Eri Sugano Naohiro Sugitani Moeko Ochiai Rei Yamaguchi Katsunori Ikari Hisashi Yamanaka Masayoshi Harigai Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. PLoS ONE |
| title | Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. |
| title_full | Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. |
| title_fullStr | Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. |
| title_full_unstemmed | Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. |
| title_short | Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. |
| title_sort | cost consequence of abatacept as first line therapy in japanese rheumatoid arthritis patients using iorra real world data |
| url | https://doi.org/10.1371/journal.pone.0277566 |
| work_keys_str_mv | AT eiichitanaka costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT eisukeinoue costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT ayakoshoji costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT jonasnilsson costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT christospapagiannopoulos costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT devenderdhanda costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT yuriyoshizawa costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT maiabe costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT kumikosaka costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT erisugano costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT naohirosugitani costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT moekoochiai costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT reiyamaguchi costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT katsunoriikari costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT hisashiyamanaka costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata AT masayoshiharigai costconsequenceofabataceptasfirstlinetherapyinjapaneserheumatoidarthritispatientsusingiorrarealworlddata |